Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Celia Martín-OtalAritz Lasarte-CiaDiego SerranoNoelia CasaresEnrique CondeFlor NavarroInés Sánchez-MorenoMarta GorraizPatricia SarriónAlfonso CalvoCarlos E De AndreaJosé EchevesteAmaia VilasJuan Roberto Rodriguez-MadozJesús San MiguelFelipe ProsperSandra Hervás-StubbsJuan Jose LasarteTeresa LozanoPublished in: Journal for immunotherapy of cancer (2022)
These results suggest that targeting the tumor-specific fibronectin splice variant EDA with CAR-T cells is feasible and offers a therapeutic option that is applicable to different types of cancer.